Q32 Bio has launched with $46m from investors including University of Colorado to target autoimmune and inflammatory diseases.
Q32 Bio, a US-based biologics developer based on research at University of Colorado and Medical University of South Carolina, has disclosed a $46m series A round featuring University of Colorado.
Venture capital firm Atlas Venture led the round, which also featured pharmaceutical firm Sanofi, healthcare provider Children’s Hospital Colorado, OrbiMed Advisors and Abingworth.
Sanofi and Children’s Hospital Colorado invested in the round through Sanofi Ventures and Children’s Hospital Colorado respectively.
Q32 Bio is working on treatments for…
